Tirzepatide Versus Semaglutide for Weight Loss: Reading the Head-to-Head Evidence

The short answer#

In the one large head-to-head trial, SURMOUNT-5, tirzepatide produced more weight loss than semaglutide: about 20.2 percent of body weight lost at 72 weeks versus 13.7 percent. In practical terms that was roughly 23 kg versus 15 kg. Tirzepatide also caused slightly fewer stomach side effects severe enough to make people stop. That said, both drugs work well, and semaglutide has something tirzepatide does not yet have: completed evidence that it lowers heart attacks and strokes. The better choice is individual, not universal.

Key points#

• SURMOUNT-5, a 72-week randomized trial of 751 adults with obesity and no diabetes, found tirzepatide reduced body weight by 20.2 percent versus 13.7 percent for semaglutide.
• In real numbers that was about 22.8 kg with tirzepatide and 15.0 kg with semaglutide, a difference near 8 kg.
• Nearly one in three tirzepatide users (31.6 percent) lost at least a quarter of their body weight, versus about one in six (16.1 percent) on semaglutide.
• Both cause mostly mild to moderate nausea, vomiting, and diarrhea early on; stomach side effects forced fewer people off tirzepatide (2.7 percent) than semaglutide (5.6 percent).
• Semaglutide has finished cardiovascular outcome data (the SELECT trial showed 20 percent fewer major heart events); tirzepatide's equivalent trial is not expected to report until around 2027.
• Both carry the same boxed warning for thyroid C-cell tumors and the same contraindications.
• Both are costly, brand-only weekly injections; insurance, cash price, and current supply often decide the real-world choice.

What are tirzepatide and semaglutide, and how do they work?#

Both belong to the incretin family, hormones your gut releases after you eat. Semaglutide (sold as Wegovy for weight management and Ozempic for diabetes) copies one of those hormones, GLP-1. Tirzepatide (sold as Zepbound for weight management and Mounjaro for diabetes) copies two at once, GLP-1 and a second gut hormone called GIP, in a single molecule. That is the core structural difference: one target versus two.

What do those signals do? They tell the pancreas to release insulin when glucose is high, slow how fast the stomach empties, and act on appetite centers in the brain so you feel full sooner and stay full longer. The result is smaller portions, fewer food cravings, and steady weight loss over months. Adding GIP pharmacology appears to raise the ceiling on how much weight comes off, and it may also blunt some of the nausea, which could explain why tirzepatide tended to be a little easier on the stomach in the trial. If you want the fuller physiology, see our companion piece, How GLP-1 Medicines Work Beyond Blood Sugar.

Both drugs are once-weekly injections under the skin, both are meant to be paired with a reduced-calorie diet and more physical activity, and both are approved for adults with a body-mass index of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea.

Is tirzepatide better than semaglutide for weight loss?#

On weight loss alone, the head-to-head data favor tirzepatide. SURMOUNT-5 randomly assigned 751 adults with obesity and no diabetes to the highest dose each could tolerate of either drug, then followed them for 72 weeks. The average weight reduction was 20.2 percent with tirzepatide and 13.7 percent with semaglutide. Waist circumference dropped 18.4 cm versus 13.0 cm. Both differences were statistically significant.

The gap is easier to feel when you look at who reached specific milestones rather than the average.

Read the bottom row as an absolute difference: for every 100 people treated, roughly 16 more reached the 25 percent mark on tirzepatide than on semaglutide. Put another way, you would treat about six or seven people with tirzepatide instead of semaglutide for one extra person to cross that threshold. That is a real edge, and it is worth keeping in proportion. A 13.7 percent loss is still a large, clinically meaningful result that improves blood pressure, blood sugar, and joint load. The honest summary is that tirzepatide is the stronger weight-loss drug on average, not that semaglutide fails. If a percentage gap tempts you to over-read the numbers, our explainer on Absolute vs Relative Risk shows why the same finding can sound dramatic or modest depending on how it is framed.

One caution about this trial: it compared the two drugs at their higher approved doses over a fixed period. Individual responses vary widely. Some people lose more on semaglutide than the trial average, and some lose less on tirzepatide.

How do the side effects and tolerability compare?#

The side-effect profiles are more alike than different. In both groups the common complaints were gastrointestinal, mostly nausea, vomiting, diarrhea, and constipation, mostly mild to moderate, and mostly during the weeks when the dose is stepped up. Slow dose escalation is the main way clinicians keep these manageable.

Two contrasts stand out. Fewer people quit tirzepatide over stomach upset, which fits the idea that GIP signaling softens nausea. On the other hand, injection-site reactions were far more common with tirzepatide, and serious adverse events were numerically a touch higher. Neither drug looked dangerous in this trial, and the discontinuation rates for both were low.

Both carry the same boxed warning: in rodents these medicines caused thyroid C-cell tumors, and although it is unknown whether that happens in people, both are contraindicated if you or a close relative has had medullary thyroid carcinoma or the syndrome called Multiple Endocrine Neoplasia type 2. Both can also raise the risk of pancreatitis, gallbladder problems, and, rarely, bowel obstruction, and both warrant caution with a history of severe gastrointestinal disease.

What about cost, access, and shortages?#

For many people this section, not the efficacy table, decides the answer. Both are brand-only medicines with high list prices, roughly in the range of 1,000 to 1,350 US dollars per month before insurance in 2026. Coverage is inconsistent. Some commercial plans cover them for obesity, many do not, and Medicare coverage remains limited unless there is a qualifying condition.

Cash-pay options have narrowed the gap. Both manufacturers now sell lower-cost self-pay vials or programs, which have brought monthly out-of-pocket costs for uninsured patients down substantially compared with the list price. These prices change often, so confirm the current figure directly with the manufacturer or pharmacy rather than trusting an older number.

Supply is also worth checking. The shortages that disrupted both drugs from roughly 2022 to 2024 have largely eased, but availability of specific doses can still fluctuate by pharmacy and region. If you start on one drug and your dose is unavailable, that practical reality sometimes drives a switch more than any trial result does.

How is the choice individualized, and where does the heart fit in?#

The weight-loss winner is not automatically your winner. A few factors tilt the decision.

Other conditions matter. If you have established cardiovascular disease, semaglutide currently has an advantage the numbers alone do not capture. In the SELECT trial of more than 17,000 adults with heart disease and overweight or obesity but no diabetes, semaglutide 2.4 mg lowered major cardiovascular events (cardiovascular death, heart attack, or stroke) by about 20 percent compared with placebo, from 8.0 percent to 6.5 percent over roughly three years. That earned it a specific cardiovascular indication. Tirzepatide's dedicated outcomes trial has not reported yet, so we do not have proof it delivers the same heart protection, even though its metabolic effects are strong. Semaglutide also has an approval for a form of fatty liver disease with fibrosis, while tirzepatide additionally carries an approval for moderate to severe obstructive sleep apnea in adults with obesity.

Goals and starting point matter. For someone with a very high BMI or a large target, the extra potency of tirzepatide is attractive. For someone in the lower obesity range who mainly needs a moderate, durable loss, semaglutide often does the job with a longer real-world track record.

Tolerance and history matter. If a person has struggled with nausea before, the slightly gentler tolerability of tirzepatide may help. If injection-site reactions are a concern, that leans the other way.

None of these medicines is a short course. Weight tends to return after stopping either one, so the decision is really about a long-term plan, including diet, activity, sleep, and follow-up, not a single number from a single trial.

When to seek care#

Contact a clinician promptly, or seek urgent care, if you notice any of the following on either drug:

• Severe or constant abdominal pain, especially pain that bores through to your back, which can signal pancreatitis.
• Persistent vomiting or diarrhea with signs of dehydration, such as dizziness, dark urine, or a racing heart.
• Right upper abdominal pain, fever, or yellowing of the skin or eyes, which can point to gallbladder disease.
• A lump or swelling in the neck, hoarseness, or trouble swallowing.
• Symptoms of low blood sugar (shakiness, sweating, confusion), more likely if you also take insulin or a sulfonylurea.
• Signs of a serious allergic reaction, such as facial swelling or trouble breathing.

Decisions about starting, switching, or stopping these medicines should be made with a licensed clinician who knows your full history.